Vaccines against HPV and HPV-related diseases

Patent metadata

Field	Value
Publication number	US-10940195-B2
Application number	US-201916397214-A
Country	US
Kind code	B2
Filing date	Apr 29, 2019
Priority date	Jan 13, 2014
Publication date	Mar 9, 2021
Grant date	Mar 9, 2021

Abstract

Embodiments relate to novel vaccines against human papillomavirus (HPV) and HPV-related diseases, including multiple types of cancers. The HPV vaccines are composed of anti-human dendritic cell (DC) surface receptor antibodies, including CD40, and E6/7 proteins of HPV16 and 18. The technology described is not limited to making vaccines against HPV16- and HPV18-related diseases and can be applied to making vaccines carrying E6/7 from any type of HPV. The HPV vaccines described can target DCs, major and professional antigen presenting cells (APCs), and can induce and activate potent HPV E6/7-specific and strong CD4+ and CD8+ T cell responses. The HPV vaccines can be used for the prevention of HPV infection and HPV-related diseases as well as for the treatment of HPV-related diseases, including cancers.

First claim

What is claimed is:

1. One or more nucleic acids encoding a fusion protein comprising an anti-CD40 antibody or fragment thereof, comprising at least three complementarity determining regions from each of a heavy and light chain variable region of an anti-CD40 antibody, at least one peptide linker and at least one human papillomavirus (HPV) E6 or E7 antigen, wherein the E6 or E7 antigen or antigens are HPV type 16 or HPV type 18 antigens, wherein the at least one HPV E6 or E7 antigen comprises a peptide comprising the amino acid sequence of at least one of SEQ ID Nos: 1, 3 and 4.

2. The one or more nucleic acids of claim 1 , wherein the anti-CD40 antibody or fragment thereof is humanized.

3. The one or more nucleic acids of claim 1 , wherein the peptide linker or linkers comprise one or more glycosylation sites.

4. The one or more nucleic acids of claim 1 , wherein the peptide linker comprises one or both of Flexv1 (SEQ ID NO:5) and f1 (SEQ ID NO:6).

5. The one or more nucleic acids of claim 1 , wherein the fusion protein comprises one HPV E6 antigen of SEQ ID NO: 1 or 3 and one HPV E7 antigen of SEQ ID NO:2 or 4.

6. The one or more nucleic acids of claim 1 , wherein at least one nucleic acid comprises the sequence of SEQ ID NO:18.

7. The one or more nucleic acids of claim 1 , wherein at least one nucleic acid comprises the sequence of SEQ ID NO:20 or 22.

8. The one or more nucleic acids of claim 1 , wherein at least one HPV E6 antigen is an HPV type 16 antigen and at least one HPV E7 antigen is an HPV type 16 antigen.

9. The one or more nucleic acids of claim 1 , wherein at least one HPV E6 antigen is an HPV type 18 antigen and at least one HPV E7 antigen is an HPV type 18 antigen.

10. The one or more nucleic acids of claim 1 , wherein at least one HPV E6 antigen is an HPV type 16 antigen and at least one HPV E7 antigen is an HPV type 18 antigen or wherein and at least one HPV E6 antigen is an HPV type 18 antigen and at least one HPV E7 antigen is an HPV type 16 antigen.

11. The one or more nucleic acids of claim 1 , wherein the fusion protein comprises the amino acid sequences of at least SEQ ID NOs:11-13 and/or SEQ ID NOs:14-16.

12. The one or more nucleic acids of claim 1 , wherein the fusion protein comprises a heavy chain variable region comprising CDR1, CDR2, and CDR3 of SEQ ID Nos: 14-16, respectively, and a light chain variable region comprising CDR1, CDR2, and CDR3 SEQ ID Nos:11-13, respectively.

13. A vector comprising the one or more nucleic acids of claim 1 .

14. An isolated host cell comprising the one or more nucleic acids of claim 1 .

15. An isolated host cell comprising a nucleic acid encoding an anti-CD40 heavy chain variable region comprising at least three complementarity determining regions, at least one peptide linker and at least one human papillomavirus (HPV) type 16 or type 18 E6 or E7 antigen, wherein the at least one HPV E6 or E7 antigen comprises a peptide comprising the amino acid sequence of at least one of SEQ ID Nos: 1, 3 and 4.

16. The cell of claim 15 , wherein the cell further comprises a nucleic acid encoding an anti-CD40 light chain variable region comprising at least three complementarity determining regions.

17. An isolated host cell comprising:
i.) a nucleic acid comprising a sequence of SEQ ID NO:20, a nucleic acid that encodes a polypeptide of SEQ ID NO: 19, a nucleic acid comprising a sequence with at least 80% identity to SEQ ID NO:20, a nucleic acid that encodes a polypeptide with at least 80% identity to SEQ ID NO: 19, a nucleic acid comprising a sequence of SEQ ID NO:22, a nucleic acid that encodes a polypeptide of SEQ ID NO:21, a nucleic acid comprising a sequence with at least 80% identity to SEQ ID NO:22, or a nucleic acid that encodes a polypeptide with at least 80% identity to SEQ ID NO:21; and
ii.) a nucleic acid comprising a sequence of SEQ ID NO: 18, a nucleic acid that encodes a polypeptide of SEQ ID NO: 17, a nucleic acid comprising a sequence with at least 80% identity to SEQ ID NO: 18, or a nucleic acid that encodes a polypeptide with at least 80% identity to SEQ ID NO: 17.

18. A method of making a fusion protein comprising expressing the one or more nucleic acids of claim 1 in a host cell and isolating the fusion protein.

19. A method of making a fusion protein comprising incubating the host cell of claim 16 and isolating the fusion protein.

Assignees

• Baylor Res Institute

Inventors

• Oh Sangkon
• Zurawski Sandra
• Zurawski Gerard

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• A61K39/395

  Antibodies (agglutinins A61K38/36 {; as drug carriers A61K47/50}); Immunoglobulins; Immune serum, e.g. antilymphocytic serum · CPC title

• C07K16/2878

  against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95 · CPC title

• A61K2039/53

  DNA (RNA) vaccination · CPC title

• C07K2319/74

  containing a fusion for binding to a cell surface receptor · CPC title